Core Insights - Twist Biosciences Corporation is highlighted as one of the most promising gene editing stocks according to analysts, with recent price target increases reflecting confidence in its performance [1][2]. Company Overview - Twist Bioscience (NASDAQ: TWST) is a biotechnology company that has developed a proprietary silicon-based DNA synthesis platform, which is essential for modern genetic research and engineering [4]. Analyst Ratings and Price Targets - Barclays raised its price target for TWST from $37 to $39 while maintaining an Overweight rating, indicating confidence in the company's margin progress and expected performance in the life sciences tools sector [1]. - Stephens initiated coverage on TWST with an Overweight rating and a price target of $41, citing the company's proprietary technology as a competitive advantage in synthetic biology and research markets [2]. Product Developments - On December 4, 2025, Twist Bioscience launched research-grade Plasmid DNA Preps aimed at supporting pre-clinical nucleic acid therapeutics research, enhancing its role as a supplier for biotech and pharmaceutical discovery workflows [3].